ClinConnect ClinConnect Logo
Search / Trial NCT00580567

Impulsivity in Pathological Gambling

Launched by UNIVERSITY OF CALIFORNIA, LOS ANGELES · Dec 20, 2007

Trial Information

Current as of April 29, 2025

Completed

Keywords

Impulsivity Gambling Pathological Gamblers Problem Gamblers Non Pathological Gamblers Risk Taking Inhibition Gambling Severity

ClinConnect Summary

Personality traits of impulsivity will be measured with the Barrett Impulsiveness Scale and the NEO Personality Inventory-Revised. Behavioral components of impulsivity will be tested through delay and probability discounting tasks. Finally, measures of frontotemporal functioning are also included in a neuropsychology and neurocognitive battery. Recent studies have shown that these areas of the brain function differently in pathological gamblers; thus, the following neuropsychology/neurocognitive tests have been included: Attention/Information Processing Speed (via Simple Reaction Time Task ...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Inclusion Criteria for Pathological Gamblers:
  • 18 years or older
  • Be able to speak, read and write in English
  • Current diagnosis of pathological gambling (using DSM-IV criteria)
  • South Oaks Gambling Screen (SOGS) score of 5 or above during screening
  • Recent gambling activity -- at least once within one week prior to enrollment.
  • Voluntarily given informed consent and signed the informed consent document.
  • Not currently seeking treatment for gambling
  • Inclusion Criteria For Control Participants:
  • 18 years or older
  • Be able to speak, read and write in English
  • South Oaks Gambling Screen (SOGS) score of 5 or less during screening
  • Voluntarily given informed consent and signed the informed consent document
  • Does not meet diagnosis of pathological gambling by DSM-IV criteria
  • Not currently seeking treatment for gambling
  • Exclusion Criteria:
  • Exclusion Criteria for all participants:
  • Current treatment for pathological gambling, excluding involvement with Gamblers Anonymous
  • Ongoing medication for any psychiatric disorders, including anti-psychotics, antidepressants, mood stabilizers, anxiolytics or sedative/hypnotics.
  • Dependence by DSM-IV criteria on any psychoactive substance, excluding caffeine or nicotine
  • Presence of clinically unstable medical disorders that could harm the subject if not treated immediately.
  • Presence of any neurological or psychiatric disorders (as assessed by the SCID or MINI and BDI-II) that would require immediate treatment.
  • Test positive urine toxicology for illicit drugs prior to enrollment
  • Hamilton Depression Scale score of \>17

About University Of California, Los Angeles

The University of California, Los Angeles (UCLA) is a prestigious academic institution renowned for its commitment to research and innovation in the biomedical field. As a clinical trial sponsor, UCLA leverages its cutting-edge facilities, expert faculty, and collaborative environment to advance medical knowledge and improve patient care. The university is dedicated to conducting rigorous clinical research that adheres to the highest ethical standards, aiming to translate scientific discoveries into effective therapies and interventions. Through its diverse array of clinical trials, UCLA seeks to address critical health challenges while fostering the development of future healthcare leaders.

Locations

Los Angeles, California, United States

Patients applied

0 patients applied

Trial Officials

Timothy W. Fong, M.D.

Principal Investigator

UCLA Gambling Studies Program

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials